PBAC's latest decision on Paritaprevir / ritonavir / ombitasvir / dasabuvir: Recommended with restriction (2015). Considered for Treatment of patients with genotype 1 chronic hepatitis C infection who have compensated liver disease, irrespective of previous treatment history.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Adults aged 18 years or older with genotype 1 chronic hepatitis C infection and compensated liver disease, treated in accredited treatment centres, with varied eligibility by genotype and prior treatment history.
Therapy area
Hepatology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
SVR
Key trials
MALACHITE I, MALACHITE II, TURQUOISE II, SAPPHIRE I, SAPPHIRE II
Comparator
no treatment, ledipasvir/sofosbuvir
Economic model
CUA
ICER note
ICER values are redacted/commercially sensitive — the document states pricing information and economic model details are redacted with asterisks throughout